# About Med Tirzepatide — independent editorial publisher

> Med Tirzepatide is an independent editorial project that publishes summaries of the peer-reviewed research literature on tirzepatide. Not a clinic. Not a vendor.

Editorial standards, sourcing methodology, and what the herbarium framing is — and is not.

## What Med Tirzepatide is

Med Tirzepatide is an independent editorial project that publishes summaries of the peer-reviewed research literature on tirzepatide. We are not a clinic. We do not employ clinicians and we do not provide medical advice. We do not manufacture, sell, or distribute any product. Our work is editorial commentary on publicly available science.

The domain name carries the modifier 'med' — a register cue, not a service claim. We chose the herbarium-pharmacopoeia framing because the materia-medica register is the most accurate description of what an independent editorial summary of an FDA-approved compound's evidence base actually is: a press of the source literature, indexed and captioned, filed by trial and outcome. The herbarium framing does not imply that we are a pharmacy, a dispensary, a clinic, a telehealth platform, or any other licensed healthcare entity. We are none of those things. We are a publication.

## Editorial standards

Every quantitative claim on this site is sourced to a primary publication, a regulatory document, or a peer-reviewed review. The references page lists every source cited. Numerical figures — half-lives, dose ranges, trial endpoints, adverse event rates — are reproduced as they appear in the primary publications, not paraphrased or rounded for emphasis. Where a trial reported a range of doses, the full range is reproduced; where a figure has a confidence interval reported by the original investigators, the interval is retained.

Brand names for the approved tirzepatide formulation are not used. We refer to the compound by its International Nonproprietary Name only — the convention adopted by independent scholarly and pharmacopoeial publications. The site does not link to any other site in the publisher's portfolio. The only outbound links are to primary sources: PubMed, PubMed Central, peer-reviewed journals, the U.S. Food and Drug Administration, and ClinicalTrials.gov.

The site does not solicit funds, sell advertising on the surface of its pages, or accept editorial sponsorship from any pharmaceutical manufacturer or telehealth platform.

## What we do not do

We do not provide medical advice. We do not recommend a dose for any individual reader. We do not provide a clinical service. We do not employ physicians, nurses, pharmacists, or any other licensed healthcare practitioners — and the editorial register of the site, which speaks in the third person about the trial record, reflects that.

The modifier 'med' in the domain name is editorial framing — a position the publisher occupies relative to the literature — and not a claim about services offered by the site. The herbarium frame is editorial license: a way of organizing the catalog of trial findings into a single legible volume, in the manner of a Victorian pharmacopeia. It is not a claim about the site's regulatory status or about any healthcare relationship between the site and its readers.

## Disclaimer

The content of this site is not medical advice. Tirzepatide is an FDA-approved prescription medicine; questions about its clinical use are appropriately addressed to a licensed prescribing clinician. Med Tirzepatide is an independent editorial pharmacopoeia — a catalog of the published research record. It is not affiliated with any vendor, manufacturer, or healthcare provider, and it does not dispense, sell, or distribute any product.

---

An independent pharmacopoeial digest of the published tirzepatide record — not a clinic, not a dispensary, not medical guidance.